Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol
Authors: Richardson Paul G. , Smith Angela , Kernan Nancy A. , Grupp Stephan A. , Arai Sally , Triplett Brandon M. , Haut Paul R. , Chan Kawah , Symons Heather J. , Horn Biljana N. , Gillio Alfred P. , Boyer Michael , Krishnan Amrita , Lehmann Leslie E. , Martin Paul L. , Mineishi Shin , Shore Tsiporah B. , Simms-Waldrip Tiffany , Antin Joseph H. , Hannah Alison L. , Hume Robin , Tudone Elena , Heringa Carin , Soiffer Robert J. ,   Defibrotide Study Group
Published: October 2019

Abstract 738

Background:

Given the life-threatening nature of severe VOD (sVOD) and associated multi-organ failure (MOF) and that there are no currently approved therapies for this condition, DF has been made available since 2007 in the USA through a prospective T-IND. The aim of the T-IND is to gather additional data on safety and response to DF in a broader patient (pt) population including those with sVOD/MOF and those with non-severe VOD. To date this is the largest prospective evaluation of DF for the treatment of sVOD/MOF in pts undergoing HSCT and pts who developed VOD following chemotherapy (non-HSCT pts). Here we provide an update on the efficacy and safety of DF in pts undergoing HSCT.

Methods:

The original T-IND protocol required pts to have a diagnosis of VOD by Baltimore criteria (total bilirubin ≥2.0 mg/dL with ≥2 of the following: hepatomegaly, ascites or 5% weight gain) with MOF (either renal and/or pulmonary failure) following HSCT, and was amended to allow inclusion of pts with non-severe VOD (defined as no MOF). Key exclusion criteria included clinically significant bleeding or the need for >1 vasopressor. Complete response (CR) was defined as bilirubin <2 mg/dL plus resolution of MOF (if applicable). Mortality was assessed at Day +100 (D+100) in all pts. DF was given at 6.25 mg/kg IV q6h (25 mg/kg/d) with recommended treatment duration of at least 21 days (d).

Results:

The current interim analysis is based on 333 VOD pts enrolled between December 2007 and September 2011 at 68 centers, 305 of which had undergone HSCT (274 allogeneic HSCT, 82%). Median age was 16 years (range 0.1–70), 55% were male and 18% had undergone multiple HSCTs (>1 HSCT). Overall, 220 pts had severe disease at study entry. The most common diagnosis was leukemia (29% AML; 22% ALL; 4 other), with conditioning of CY (69%), BU (45%) and TBI (39%), respectively. Median onset of VOD was 16 d post-HSCT. Overall, 30% (90/305) of HSCT pts achieved CR and 50% (Kaplan-Meier estimate) survived to D+100. In HSCT pts with sVOD, CR was 26% and D+100 survival was 45%. For the HSCT pts with non-severe VOD, CR and D+100 survival was 39% and 65%, respectively. In the T-IND, 155 pts matched the entry criteria for the original phase III trial and were compared to the phase III historical controls (HCs) who did not receive DF. Results showed a statistically improved outcome in CR (29% vs 9%, p=0.0019) and D+100 survival (49% vs 25%, p=0.0016) compared with HCs. In all pts, delay of >2 d (vs ≤2 d) in the start of DF after VOD diagnosis resulted in reduced CR (20% vs 34%, p=0.0195) and survival (Kaplan-Meier estimate) (37% vs 56%, p=0.0118). Children (≤16 years) as compared to adults had higher CR rates (33% vs 26%, p=0.187) and survival (56% vs 44%, p=0.0277). Toxicity proved generally manageable: 21% of pts experienced a total of 92 related AEs, primarily consisting of hemorrhage (18%) and hypotension (4%). Hemorrhage included pulmonary bleeding (6%), GI hemorrhage (4%), epistaxis (2%) and hematuria (2%), with 2% of pts experiencing life threatening hemorrhage in which a possible relationship with DF could not be ruled out. Similar to the observation of decreased GvHD in other studies, the incidence of all grade GvHD in the allogeneic HSCT pts was 8%.

Conclusions:

DF therapy in sVOD/MOF pts achieved significantly improved outcomes compared to HCs. Based on the results of this large cohort of pts, early treatment with DF (i.e. within 2 d of VOD diagnosis) is recommended, and consistently improved outcomes are seen in pts who have not yet progressed to sVOD. Generally, DF was well-tolerated and as with prior studies, there was a low incidence of DF-associated toxicities. These results confirm the findings of previous trials and strongly support early intervention with DF once the diagnosis of VOD is made after HSCT. Outcomes in children appear to be even better than in adults, supporting the importance of this agent in the pediatric population in particular. In addition, low rates of GvHD were seen and this is an area in which further studies are planned. Enrollment to the T-IND study continues.

Disclosures:

Richardson: Gentium: Advisory committee Other. Hannah:Gentium: Consultancy. Hume:Gentium: Employment. Tudone:Gentium: Employment. Heringa:Gentium: Employment. Study Group:Gentium: Employment.